-

 CORRECTING and REPLACING Croma Aesthetics Canada Launches saypha® VOLUME PLUS

Company will focus on untapped demographic groups that value aesthetics and a new definition of luxury

CORRECTION...by Croma Aesthetics Canada Ltd.

TORONTO--(BUSINESS WIRE)--First paragraph, first sentence of release should read: Croma Aesthetics Canada Ltd., doing business as Hugel Aesthetics is pleased to announce the launch of saypha® VOLUME PLUS, a hyaluronic acid dermal filler product specifically designed to restore facial volume.

The updated release reads:

CROMA AESTHETICS CANADA LAUNCHES SAYPHA® VOLUME PLUS

Company will focus on untapped demographic groups that value aesthetics and a new definition of luxury

Croma Aesthetics Canada Ltd., doing business as Hugel Aesthetics is pleased to announce the launch of saypha® VOLUME PLUS, a hyaluronic acid dermal filler product specifically designed to restore facial volume.1 The launch of saypha® VOLUME PLUS into the Canadian market will enhance the available line of saypha® dermal fillers, giving aesthetic medical professionals more creative power to design a truly bespoke experience for their patients.

saypha® VOLUME PLUS launches at a time when the aesthetic injectables market is on the fast track to growth thanks to emerging Aesthetic Next consumer segments including men and millennials.2 With this launch, Hugel Aesthetics aims to appeal to a broader and more youthful consumer demographic than current fillers on the market. The associated marketing campaign for saypha® VOLUME PLUS is designed to specifically capture the needs and wants of this Aesthetic Next generation by redesigning the filler experience from discovery to purchase.

“What constitutes luxury today takes on a modern, new meaning with our target consumer. For them, luxury is about an affordable, authentic, and transparent experience with a quality product that makes them feel special,” said Bob Bennett, GM of Hugel Aesthetics. “At Hugel Aesthetics we are committed to tailoring and elevating the consumer’s experience with our brands in ways that surprise and delight, and the launch of the saypha® VOLUME PLUS product is just the beginning for us."

saypha® products are available throughout Canada. Providers are encouraged to contact their Evolve Medical Representative or email cscanada@hugel-aesthetics.com for product and ordering information.

About saypha®

The Croma HA filler range available in Canada consists of three products: saypha® FILLER Lidocaine, saypha® VOLUME Lidocaine and saypha® VOLUME PLUS.

The products target individual needs of the patients:

saypha® FILLER Lidocaine is indicated to correct light to moderate nasolabial folds. The product is injected into the mid to deep dermis.3

saypha® VOLUME Lidocaine is indicated for the correction of deeper wrinkles in the nasolabial folds. The product is injected into a deeper skin layer (deep dermis).4

saypha® VOLUME PLUS is indicated to correct moderate to severe midface volume deficit in the zygomaticomalar region, anteromedial cheek region and submalar region. The product is injected deep subcutaneously or supraperiosteally. 1

All products are based on non-animal derived hyaluronic acid and are manufactured in accordance with the highest safety and quality standards.

As with any medical procedure, there is always a risk of unwanted side effects with HA facial filler treatments. Patients should speak with their doctor about the benefits and risk of any procedure.

The saypha® range of fillers should only be administered by a trained and qualified medical aesthetics healthcare practitioner. For more information, visit www.saypha.ca.

About Croma/ Hugel Aesthetics

Croma Aesthetics Canada Ltd. is subsidiary of Hugel America, Inc. (Hugel Aesthetics), a growth focused joint venture between aesthetic market-leading partners Hugel Inc., and Croma to develop and commercialize botulinum toxin, hyaluronic acid fillers, and additional aesthetic portfolio products in the United States, Canada, Australia, and New Zealand. Hugel Aesthetics is dedicated to making a difference by transforming patient experiences. For more information, visit us at www.hugel-aesthetics.com

References

1. saypha® VOLUME PLUS Lidocaine Instructions for Use

2. Leclerc, O., Peters, N., Scaglione, A., Waring,J. (2021, December 21). From extreme to mainstream: The future of aesthetics injectables. McKinsey &Company. https://www.mckinsey.com/industries/life-sciences/our-insights/from-extreme-to-mainstream-the-future-of-aesthetics-injectables

3. saypha® FILLER Lidocaine Instructions for Use

4. saypha® VOLUME Lidocaine Instructions for Use

Contacts

Kayleigh Adam
kayleigha@abmc-us.com
212.230.1800

Croma Aesthetics Canada Ltd.


Release Versions

Contacts

Kayleigh Adam
kayleigha@abmc-us.com
212.230.1800

More News From Croma Aesthetics Canada Ltd.

Croma Australia Pty Ltd, a subsidiary of Hugel Aesthetics, Receives TGA Approval in Australia for LETYBO (letibotulinumtoxinA) for the Treatment of Glabellar Lines

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Hugel America, Inc., (Hugel Aesthetics), today announced it received Therapeutic Goods Administration (TGA) approval for LETYBO (letibotulinumtoxinA) to treat moderate-to-severe glabellar (frown) lines in adults. "We are thrilled with the TGA’s approval of LETYBO. This is a major milestone for Croma Australia as we focus on becoming a top aesthetics brand in Australia,” stated James Hartman, President, Hugel Aesthetics. “We are excited to deliver quality...

Hugel Aesthetics Receives FDA Acceptance of BLA Resubmission for LetibotulinumtoxinA for Injection for Glabellar Lines

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Hugel America, Inc. (Hugel Aesthetics) announced today the acceptance of its Biologics License Application for letibotulinumtoxinA, by the U.S. Food and Drug Administration (“FDA”). The FDA considered the resubmission a Class 2 response and has assigned a April 6, 2023 action date per the Prescription Drug User Fee Act (PDUFA). Jim Hartman, President of Hugel Aesthetics, stated, “We have worked diligently to advance our regulatory submission of letibotuli...

Hugel Aesthetics Resubmits Biologics License Application for LetibotulinumtoxinA for Injection for Glabellar Lines to the FDA

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Hugel America, Inc. (Hugel Aesthetics) announced today that it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for letibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines. The resubmission follows the receipt of a Complete Response Letter (CRL) from the FDA in March 2022, which required additional data to complete the review of the BLA. Deficiencies cited by the FDA i...
Back to Newsroom